|
|
|
| Effect of Trastuzumab Combined With Sox Chemotherapy on HER-2 Positive Advanced Gastric Cancer and Progression Free Survival |
| Jiao Yang |
| Department of Pharmacy,Kaifeng Cancer Hospital,Kaifeng 475000,China |
|
|
|
|
Abstract Objective To investigate the efficacy of trastuzumab combined with Sox chemotherapy in the treatment of advanced gastric cancer with positive human epidermal growth factor receptor-2（HER-2）and its effect on progression free survival（PFS）. Methods 116 patients with HER-2 positive advanced gastric cancer were randomly divided into two groups,58 cases in each group.The control group was given Sox chemotherapy,and the observation group was given trastuzumab combined with Sox chemotherapy.The clinical efficacy,adverse reactions（leucopenia,neutropenia,thrombocytopenia,anemia,nausea,vomiting,mucositis）and PFS were compared between the two groups. Results After treatment,the Objective remission rate（RR）and disease control rate（DCR）of the observation group were 67.24% and 89.66%,respectively,which were higher than 48.28% and 72.41% of the control group,the difference was statistically significant（P<0.05）;during the treatment,there was no significant difference in the incidence of adverse reactions between the two groups（P>0.05）;the PFS time in the observation group was longer than that in the control group,the difference was statistically significant（P<0.05）. Conclusion Trastuzumab combined with Sox chemotherapy regimen can effectively improve the clinical efficacy of the treatment of HER-2 positive advanced gastric cancer,prolong the PFS time of patients,and do not significantly increase the toxicity and side effects,which is worthy of clinical promotion.
|
|
Received: 05 December 2020
|
|
|
|
|
|
[1] 高金平,韩涛,朴瑛,等.阿帕替尼联合替吉奥治疗老年或瘦弱患者晚期胃癌临床研究[J].临床军医杂志,2017,45(1):9-12.
[2] 谢文健,闵江,钱昆,等.多西他赛或伊立替康联合奥沙利铂及替吉奥治疗晚期胃癌的临床疗效及安全性分析[J].重庆医学,2017,46(19):2644-2648.
[3] 张宝,郑志超.进展期胃癌淋巴结清扫研究进展[J].实用肿瘤学杂志 ,2019,33(1):78-81.
[4] 邱佳宁,韩涛,刘璐,等.曲妥珠单抗联合多西他赛加顺铂治疗HER-2阳性晚期胃癌相关射血分数降低与疗效关系[J].临床军医杂志,2017,45(1):34-37.
[5] 白玉贤,马仲娟,苏颖玲,等.胃癌患者FHIT、hMLH1、p16、RAR-beta、Reprimo和TIMP3基因的甲基化研究[J].实用肿瘤学杂志 ,2019,33(1):8-13.
[6] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):25-30.
[7] 郎丰平,赵毓毅,范鹏.甲磺酸阿帕替尼治疗晚期胃癌的疗效及安全性分析[J].实用癌症杂志,2017,32(6):996-998. |
|
|
|
2021, Vol. 41 
